Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.
The collaboration will initially focus on leveraging Thermo Fisher’s RNA and advanced formulations facility to support the industrialization of Mirai’s development candidates, according to the release (1). In addition to technical collaboration, the agreement includes a direct investment into Mirai as part of the broader partnership between Thermo Fisher and
·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.
·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.
·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.
“This collaboration is an expansion of our long-standing relationship with Thermo Fisher and a reflection of our shared vision for accelerating the development of enabling technologies to develop first-in-class therapies,” said Justine
Mirai offers end-to-end services for partners in the genetic medicine space. The company’s machine intelligence-based platform enables high-throughput design and in vivo testing of targeted delivery systems, facilitating rapid and scalable development processes.
“Thermo Fisher is a trusted industry leader with deep technical expertise and proven developmental and GMP services and commercial manufacturing capabilities,” said Travis Wilson, executive chairman of Mirai and growth partner, Flagship Pioneering, in the release from Mirai (1). “Coupling these with Mirai’s unique delivery and genetic medicine optimization technologies will support accelerated program development and commercialization for our life science partners worldwide. We’re thrilled to enter into this collaboration to further strengthen Mirai’s platform and fully realize our vision of co-creating targeted, potentially curative programmable medicines with end-to-end optimization.”
This new collaboration is part of an ongoing effort by both organizations to address key challenges in genetic medicine development and to jointly create integrated solutions that can support the next wave of therapeutic innovation (1).
Thermo Fisher is focused on working sustainably. Adam Goldstein, senior director of R&D Collaborations at Thermo Fisher Scientific,
Goldstein went on to emphasize the importance of the innovations that result from adopting a sustainability-by-design approach because they can lead to improved product quality and process efficiency. “Driving higher titer in smaller volumes means yielding higher throughput of product in a smaller footprint. The benefits are lower cost of goods in manufacturing while simultaneously delivering the product in a much more sustainable fashion with regards to emissions reductions,” he commented (2).
Read the full article on
References
